 CAMBRIDGE, Mass.--BUSINESS WIRE--Axcella Nasdaq: AXLA, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator EMM compositions, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update. The year 2020 was a key inflection point for Axcella as we completed multiple clinical studies with positive results and shifted our full attenti 